Download PDF
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease
Shan Hong; Yiwei Hao; Lei Sun; Ping Li; Junru Yang; Fuyang Zhang; Lingling He; Jing Zhang; Hongshan Wei;
10.1016/j.aohep.2024.101589
Examining the prevalence of hepatic steatosis and advanced fibrosis using non-invasive measures across Canada: A national estimate using the Canadian Health Measures Survey (CHMS) from 2009-2019
Jacob Romano; Jessica Burnside; Giada Sebastiani; Alnoor Ramji; Keyur Patel; Mark Swain; Sahar Saeed;
10.1016/j.aohep.2024.101757
FLI and FIB-4 in diagnosing metabolic dysfunction-associated steatotic liver disease in primary care: High prevalence and risk of significant disease
Mário Reis Álvares-da-Silva; Márcia da Silva Vargas; Soheyla Mohd Souza Rabie; Gabriella Jonko; Patricia Gabriela Riedel; Larisse Longo; Marcelo Rodrigues Gonçalves; Vivian Cristine Luft; Dvora Joveleviths;
10.1016/j.aohep.2024.101584